Will The New Math Of Oncology Drug Review Times Carry Over Into PDUFA V?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Office of Hematology and Oncology Products originally targeted a four-month review goal for vismodegib, but review staff deemed such a compressed timeline not feasible.